-+ 0.00%
-+ 0.00%
-+ 0.00%

Kura Oncology posts corporate presentation on KOMZIFTI launch, ziftomenib pipeline strategy

PUBT·08/12/2026 21:48:00
Listen to the news
Kura Oncology posts corporate presentation on KOMZIFTI launch, ziftomenib pipeline strategy
  • Kura highlighted KOMZIFTI (ziftomenib) for adult relapsed or refractory NPM1-mutated AML, citing early launch momentum.
  • 2Q 2026 KOMZIFTI net product revenue of USD 9.1 million, up 57% from 1Q; about 115 new patient starts.
  • Cash and investments of USD 519 million as of June 30, 2026; USD 180 million of anticipated collaboration payments.
  • Kyowa Kirin collaboration: 50/50 U.S. co-development and co-promotion; Kura books 100% U.S. sales.
  • Funding expected to support the ziftomenib AML program through topline results from Phase 3 KOMET-017, anticipated in 2028.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief on August 12, 2026, and is solely responsible for the information contained therein.